Skip to main content
SpringerLink
Log in

Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Anticardiolipin antibodies (aCL) or lupus anticoagulants (LA) have been found to exert an inhibitory action upon the activation and function of protein C, a natural coagulation inhibitor. Recently an in vitro phenomenon called resistance to activated protein C (APC resistance) has been described as the most frequent cause of hereditary thrombophilia. In order to see whether a positive association of APC resistance with aCL exists we examined plasma of 162 consecutive outpatients referred for thrombophilia screening. Further, the IgG fraction was isolated from plasma of two aCL-positive and LA-negative patients and of two aCL-negative healthy subjects by means of protein A affinity chromatography. Each of these isolates was mixed with normal plasma, and the APC resistance was assayed; 25/162 (15.4%) patients had confirmed abnormal APC resistance. Only 1/25 (4.0%) APC resistance-positive patients and 11/137 (8.0%) APC resistance-negative patients had positive IgG- and/or IgM-aCL (p=0.5, nonsignificant). In the in vitro test system the APC resistance ratio remained unaffected after addition of normal IgG or aCL-IgG fraction in the tested normal plasma and did not deviate from the range of buffer controls. These data do not suggest any association of aCL with abnormal APC resistance. aCL-IgG fractions from aCL-positive and LA-negative plasmas do not interfere with the APC resistance test system in vitro in low concentration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bertina RM, Koelman PC, Koster T, et al (1994) Mutation in blood coagulation factor V, associated with resistance to activated protein C. Nature 369:64–67

    PubMed  Google Scholar 

  2. Bokarewa MI, Blombäck M, Egberg N, Roséen S (1994) A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 5:37–41

    PubMed  Google Scholar 

  3. Borrell M, Sal N, de Carsellarnau C, Lopez S, Fontcuberta J (1992) Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 68:268–272

    PubMed  Google Scholar 

  4. Cadroy Y, Sié P, Boneu B (1994) Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 83:2008–2009

    PubMed  Google Scholar 

  5. Cariou R, Tobelem G, Bellucci S, et al (1988) Effect of lupus anticoagulant on antithrombotic properties of endothelial cells. Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 60:54–58

    PubMed  Google Scholar 

  6. Carreras LO, Vermylen J (1991) Antiphospholipid antibodies and impairment of prostacyclin synthesis by endothelium. In: Harris EN, Exner T, Hughes GRV, Asherson R (eds) Phospholipid binding antibodies. CRC Press, Boca Raton, pp 231–245

    Google Scholar 

  7. Dahlbäck B (1995) Inherited thrombophilia: resistance to activated protein C a pathogenic factor of venous thromboembolism. Blood 85:607–614

    PubMed  Google Scholar 

  8. Dahlbäck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004–1008

    PubMed  Google Scholar 

  9. De Groot PhG, Derksen RHWM (1994) Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 3:229–233

    PubMed  Google Scholar 

  10. De Groot PhG, Oosting JD, Derksen RHWM (1993) Antiphospholipid antibodies: specificity and pathophysiology. Bailleres Clin Haematol 6:691–709

    Google Scholar 

  11. Exner T (1993) Some recent developments with lupus anticoagulants. Blood Coagul Fibrinolysis 5:281–289

    Google Scholar 

  12. Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP (1986) An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipids on purified endothelial thrombomodulin activity. A mechanism for thrombosis Thromb Haemost 55:309–313

    PubMed  Google Scholar 

  13. Galli M, Bevers EM (1994) Inhibition of phospholipid-dependent coagulation reactions by “antiphospholipid antibodies”: possible modes of action Lupus. 3:223–228

    PubMed  Google Scholar 

  14. Galli M, Comfurius P, Barbui T, et al (1992) Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68:297–300

    PubMed  Google Scholar 

  15. Gschwandner ME, Lechner K, Pabinger I (1995) Erroneously low APC ratio in patients with lupus anticoagulant. Ann Hematol 70:169–170

    PubMed  Google Scholar 

  16. Halbmayer WM, Haushofer A, Schön R, Fischer M (1994) Influence of lupus anticoagulant on a commercially available kit for APC resistance. Thromb Haemost 72:645–646

    PubMed  Google Scholar 

  17. Harris EN (1990) Antiphospholipid antibodies. Br J Haematol 74:1–9

    Google Scholar 

  18. Koster T, Rosendaal RS, de Tonde H, Briet E, Bandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503–1506

    PubMed  Google Scholar 

  19. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI (1995) Use of a generally applicable tissue factor dependent factor Va assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 85:1704–1711

    PubMed  Google Scholar 

  20. Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 112:682–698

    PubMed  Google Scholar 

  21. Malia RG, Kitchen S, Greaves M, Preston FE (1990) Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 76:101–107

    PubMed  Google Scholar 

  22. Marciniak E, Romond EH (1989) Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 74:2426–2432

    PubMed  Google Scholar 

  23. Oosting JD, Derksen RHWM, Bobbing WG, Hackeng TM, Bouma BM, de Groot PhG (1993) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 81:2618–2625

    PubMed  Google Scholar 

  24. Oosting JD, Preissner KT, Derksen RHWM, de Groot PhG (1993) Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 85:761–768

    PubMed  Google Scholar 

  25. Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G (1995) Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 125:56–65

    PubMed  Google Scholar 

  26. Svensson PJ, Dahlbäck B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517–522

    PubMed  Google Scholar 

  27. Tobelem G (1990) Les anticorps antiphospholipides: spécificité et méchanismes d'action. Ann Med Interne (Paris) 141:257–260

    Google Scholar 

  28. Triplett DA, Brandt J (1989) Laboratory identification of the lupus anticoagulant. Br J Haematol 73:139–142

    PubMed  Google Scholar 

  29. Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F (1989) Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost 61:175–177

    PubMed  Google Scholar 

  30. Tsakiris DA, Settas L, Makris PE, Marbet GA (1990) Lupus anticoagulant, antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 17:785–789

    PubMed  Google Scholar 

  31. Zoller B, Dahlbäck B (1994) Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536–1538

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hemostasis Laboratory DCL, University Hospital Basel, CH-4031, Basel, Switzerland

    D. A. Tsakiris, M. -L. Yasikoff, F. Wolf & G. A. Marbet

Authors
  1. D. A. Tsakiris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. -L. Yasikoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. A. Marbet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsakiris, D.A., Yasikoff, M.L., Wolf, F. et al. Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro. Ann Hematol 71, 195–198 (1995). https://doi.org/10.1007/BF01910318

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01910318

Key words

Search

Navigation